Trials
5 active
10 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.”In the company’s words, NCT06976190 on ClinicalTrials.gov
- Tested for
- Recurrent or Metastatic Nasopharyngeal Carcinoma (2 trials), Squamous Cell Carcinoma of the Head and Neck, Advanced Solid Tumors
- Main trialPhase 3
- “The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.”In the company’s words, NCT05751512 on ClinicalTrials.gov
Other drugs for Recurrent or Metastatic Nasopharyngeal Carcinoma
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up3
- Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN | |
| Phase 3Recruiting | May 2029 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | |
| Phase 2Active, not recruiting | 30 Dec 2024 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma | |
| Phase 1/2Recruiting | Aug 2027 | A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors | |
| Phase 2Terminated | 12 Oct 2022 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. | |
| Phase 2Completed | 20 Oct 2022 | A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | |
| Phase 2Completed | 27 Mar 2023 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer | |
| Phase 2Completed | 26 Jul 2024 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | |
| Phase 1Completed | 29 Mar 2021 | A Study of MRG003 in Patients With Advanced Solid Tumors | |
| Phase 2Authorised | not given | Randomized Phase 2 trial of induction treatment of anti-PD-1 pucotenlimab and EGFR-ADC MRG003 or EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (LA-SCCHN). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026